At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Cetuximab +2 moredrug
Likely dose
Cetuximab 500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With KRAS Wild Type Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Cetuximab, Oxaliplatin, and 1 other intervention for Colorectal Cancer and Neoplasm Metastasis. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
This is a Phase II, open label, non-randomized study in subjects with histologically confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who have not received prior chemotherapy for metastatic disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Neoplasm Metastasis
CountriesUnited States
CollaboratorsEli Lilly and Company, Bristol-Myers Squibb
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
First PostedMar 2007
Primary CompletionAug 2012
Study CompletionJun 2015
TodayJul 2026
First PostedMar 8, 2007
Enrollment StartJun 1, 2004
Primary CompletionAug 1, 2012
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 19.3 years ago
Interventions
Cetuximabdrug
500 mg/m2, IV every two weeks
Oxaliplatindrug
85 mg/m2, IV, q 2 weeks
Capecitabinedrug
2500 mg, po bid x 7 days every two weeks